PT - JOURNAL ARTICLE AU - Stringhini, Silvia AU - Wisniak, Ania AU - Piumatti, Giovanni AU - Azman, Andrew S. AU - Lauer, Stephen A. AU - Baysson, Hélène AU - De Ridder, David AU - Petrovic, Dusan AU - Schrempft, Stephanie AU - Marcus, Kailing AU - Yerly, Sabine AU - Vernez, Isabelle Arm AU - Keiser, Olivia AU - Hurst, Samia AU - Posfay-Barbe, Klara M. AU - Trono, Didier AU - Pittet, Didier AU - Gétaz, Laurent AU - Chappuis, François AU - Eckerle, Isabella AU - Vuilleumier, Nicolas AU - Meyer, Benjamin AU - Flahault, Antoine AU - Kaiser, Laurent AU - Guessous, Idris TI - Repeated seroprevalence of anti-SARS-CoV-2 IgG antibodies in a population-based sample AID - 10.1101/2020.05.02.20088898 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.02.20088898 4099 - http://medrxiv.org/content/early/2020/05/06/2020.05.02.20088898.short 4100 - http://medrxiv.org/content/early/2020/05/06/2020.05.02.20088898.full AB - Background Assessing the burden of COVID-19 based on medically-attended case counts is suboptimal given its reliance on testing strategy, changing case definitions and the wide spectrum of disease presentation. Population-based serosurveys provide one avenue for estimating infection rates and monitoring the progression of the epidemic, overcoming many of these limitations.Methods Taking advantage of a pool of adult participants from population-representative surveys conducted in Geneva, Switzerland, we implemented a study consisting of 8 weekly serosurveys among these participants and their household members older than 5 years. We tested each participant for anti-SARS-CoV-2-IgG antibodies using a commercially available enzyme-linked immunosorbent assay (Euroimmun AG, Lübeck, Germany). We estimated seroprevalence using a Bayesian regression model taking into account test performance and adjusting for the age and sex of Geneva’s population.Results In the first three weeks, we enrolled 1335 participants coming from 633 households, with 16% <20 years of age and 53.6% female, a distribution similar to that of Geneva. In the first week, we estimated a seroprevalence of 3.1% (95% CI 0.2-5.99, n=343). This increased to 6.1% (95% CI 2.69.33, n=416) in the second, and to 9.7% (95% CI 6.1-13.11, n=576) in the third week. We found that 5-19 year-olds (6.0%, 95% CI 2.3-10.2%) had similar seroprevalence to 20-49 year olds (8.5%, 95%CI 4.99-11.7), while significantly lower seroprevalence was observed among those 50 and older (3.7%, 95% CI 0.99-6.0, p=0.0008).Interpretation Assuming that the presence of IgG antibodies is at least in the short-term associated with immunity, these results highlight that the epidemic is far from burning out simply due to herd immunity. Further, no differences in seroprevalence between children and middle age adults are observed. These results must be considered as Switzerland and the world look towards easing restrictions aimed at curbing transmission.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.covicare24.com/s/Protocole_SEROCOV-POP3003.pdf Funding StatementThis study was funded by the Swiss Federal Office of Public Health, The Swiss School of Public Health, the Fondation de Bienfaisance du Groupe Pictet, the Fondation Ancrage, the Fondation Privee des HUG, the Center for Emerging Viral Diseases. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be made available upon reasonable request at the completion of the study through contacting the study PI, Silvia.Stringhini{at}hcuge.ch.